We are live on ! Find out more
APLT

Applied Therapeutics

Delisted

APLT was delisted on the 2nd of February, 2026.

75 hedge funds and large institutions have $27.4M invested in Applied Therapeutics in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 30 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more call options, than puts

Call options by funds: $131K | Put options by funds: $76K

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

17% less funds holding

Funds holding: 9075 (-15)

28.93% less ownership

Funds ownership: 91.14%62.2% (-29%)

47% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 30

47% less capital invested

Capital invested by funds: $51.8M → $27.4M (-$24.5M)

52% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 29

Holders
75
Holders Change
-15
Holders Change %
-16.67%
% of All Funds
0.99%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
14
Increased
16
Reduced
30
Closed
29
Calls
$131K
Puts
$76K
Net Calls
+$55K
Net Calls Change
-$74K
Name Holding Trade Value Shares
Change
Change in
Stake
T. Rowe Price Investment Management
1
T. Rowe Price Investment Management
Maryland
$5.79M +$3.21M +8,303,400 +80%
VPC
2
Vestal Point Capital
New York
$3.58M
PBM
3
Propel Bio Management
California
$3.51M
KCM
4
Knoll Capital Management
Florida
$2.43M
BlackRock
5
BlackRock
New York
$1.62M -$1.68M -4,331,616 -45%
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.47M -$447K -1,155,180 -20%
SAM
7
Simplify Asset Management
Nevada
$1.4M
Pathstone Holdings
8
Pathstone Holdings
New Jersey
$822K +$1.02M +2,643,540 New
TCM
9
Tang Capital Management
California
$755K
RSCM
10
Rock Springs Capital Management
Maryland
$646K +$426 +1,100 +0.1%
Franklin Resources
11
Franklin Resources
California
$623K
Millennium Management
12
Millennium Management
New York
$605K +$710K +1,835,806 +1,683%
Qube Research & Technologies (QRT)
13
Qube Research & Technologies (QRT)
United Kingdom
$567K -$45K -116,435 -6%
Marshall Wace
14
Marshall Wace
United Kingdom
$479K +$91.6K +236,810 +18%
Adage Capital Partners
15
Adage Capital Partners
Massachusetts
$377K -$290K -750,000 -38%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$301K -$458K -1,182,851 -55%
UBS Group
17
UBS Group
Switzerland
$258K +$126K +325,538 +64%
Goldman Sachs
18
Goldman Sachs
New York
$227K +$160K +414,488 +131%
Deutsche Bank
19
Deutsche Bank
Germany
$193K -$1.49M -3,844,358 -86%
Two Sigma Investments
20
Two Sigma Investments
New York
$185K -$142K -366,053 -38%
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$183K +$58.8K +151,867 +35%
Citadel Advisors
22
Citadel Advisors
Florida
$147K +$183K +474,094 New
Charles Schwab
23
Charles Schwab
California
$126K -$88.6K -229,015 -36%
State Street
24
State Street
Massachusetts
$110K -$618K -1,598,532 -82%
Morgan Stanley
25
Morgan Stanley
New York
$107K -$979K -2,529,588 -88%

APLT Hedge Fund Activity: Q2 2025 in Review

75 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Applied Therapeutics (APLT) for Q2 2025, worth a combined $27.4M — down 47% from $51.8M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of APLT and 14 opened new positions — a net loss of 15 holders — while 30 trimmed existing stakes and 16 added.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $3.21M. The largest seller was VR Adviser, exiting entirely with an estimated $2.72M sold.

  • 75 institutional investors held Applied Therapeutics (APLT) as of Q2 2025, down from 90 in Q1 2025.
  • Funds reported $27.4M of Applied Therapeutics stock for Q2 2025, down 47% quarter-over-quarter.
  • 14 funds opened new Applied Therapeutics positions in Q2 2025 and 29 closed out, a net change of -15 holders.
  • The largest Applied Therapeutics buyer in Q2 2025 was T. Rowe Price Investment Management, an estimated $3.21M added.
  • The largest Applied Therapeutics seller in Q2 2025 was VR Adviser, an estimated $2.72M sold.

Based on aggregated 13F filings for Q2 2025.